表紙
市場調査レポート

特発性肺線維症:パイプライン製品の分析

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232804
出版日 ページ情報 英文 258 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
特発性肺線維症:パイプライン製品の分析 Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 258 Pages
概要

特発性肺線維症(IPF)は、肺の孤立性の進行性疾患です。空咳、息切れ(特に運動中/運動後)、持続的な疲労、体重減少などの症状が見られます。治療は、抗酸化剤、生物学的反応修飾物質、抗線維化剤、抗凝固剤などが含まれます。

当レポートでは、特発性肺線維症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

特発性肺線維症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AdAlta Pty Ltd.
  • Aeolus Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • Auspex Pharmaceuticals, Inc.
  • Biogen Idec Inc.
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Carolus Therapeutics, Inc.
  • Celgene Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Compugen Ltd.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Five Prime Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • HanAll Biopharma Co., Ltd.
  • Histocell S.L.
  • iBio, Inc.
  • ImmuneWorks, LLC
  • Inventiva SAS
  • Kadmon Corporation, LLC
  • Kasiak Research Pvt. Ltd.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lanthio Pharma B.V.
  • LTT Bio-Pharma Co., Ltd.
  • MedImmune, LLC
  • Moerae Matrix, Inc.
  • MSM Protein Technologies, Inc.
  • Pacific Therapeutics Ltd.
  • Pharmaxis Limited
  • Progenra, Inc.
  • Promedior, Inc.
  • ProMetic Life Sciences Inc.
  • Pulmatrix, Inc.
  • Sanofi
  • Therametrics holding AG

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • BMS-986020
  • BOT-191
  • CC-539
  • CC-90001
  • CGEN-25009
  • CKD-942
  • CT-2009
  • FG-3019
  • FPA-008
  • GKT-137831
  • GKT-901
  • HC-016
  • HL-156FIB
  • HR-017
  • IBIOCFB-03
  • ICG-001
  • interferon gamma-1b
  • IVA-337
  • IW-001
  • KBP-7018
  • KD-025
  • lebrikizumab
  • LP2
  • LT-0011
  • LTI-03
  • MMI-0100
  • Monoclonal Antibody for Idiopathic Pulmonary Fibrosis
  • MSM-735
  • NAS-911
  • nintedanib
  • omipalisib
  • PBF-1250
  • PBI-4050
  • pirfenidone
  • PRM-151
  • PUR-1500
  • PXS-25
  • PXS-4820
  • PXS-64
  • Refacell-IPF
  • RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis
  • SAR-156597
  • SD-560
  • simtuzumab
  • Small Molecule 2 for Chronic Respiratory Diseases
  • Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis
  • Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis
  • Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis
  • SPL-334
  • Stem Cell Therapy for Idiopathic Lung Fibrosis
  • Stem Cell Therapy for Lung Fibrosis
  • STX-100
  • TD-139
  • tipelukast
  • tralokinumab
  • vismodegib
  • ZL-2102

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7818IDB

Summary

Global Markets Direct's, 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2016', provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
  • The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Pulmonary Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview
    • Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis
  • Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies
  • Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic Pulmonary Fibrosis - Products under Development by Companies
  • Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
  • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
    • AdAlta Pty Ltd.
    • Aeolus Pharmaceuticals, Inc.
    • Afferent Pharmaceuticals, Inc.
    • AnaMar AB
    • Antitope Limited
    • Biogen, Inc.
    • Bioneer Corporation
    • BiOrion Technologies B.V.
    • Bristol-Myers Squibb Company
    • Carolus Therapeutics, Inc.
    • Celgene Corporation
    • Chong Kun Dang Pharmaceutical Corp.
    • Compugen Ltd.
    • Cynata Therapeutics Limited
    • Elsalys Biotech SAS
    • F. Hoffmann-La Roche Ltd.
    • FibroGen, Inc.
    • Galapagos NV
    • GenKyoTex S.A.
    • GlaxoSmithKline Plc
    • Global Blood Therapeutics, Inc.
    • HanAll Biopharma Co., Ltd.
    • HEC Pharm Co., Ltd.
    • Histocell S.L.
    • iBio, Inc.
    • Inventiva
    • Isarna Therapeutics GmbH
    • Kadmon Corporation, LLC
    • Kasiak Research Private Limited
    • Kolltan Pharmaceuticals, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Moerae Matrix, Inc.
    • MorphoSys AG
    • Novartis AG
    • Pacific Therapeutics Ltd.
    • Pharmaxis Limited
    • Promedior, Inc.
    • ProMetic Life Sciences Inc.
    • Pulmatrix, Inc.
    • Respira Therapeutics, Inc.
    • Ribomic Inc.
    • Saje Pharma, LLC
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Yuhan Corporation
  • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (acetylcysteine + pentoxifylline) - Drug Profile
    • acALY-18 - Drug Profile
    • AEOL-10150 - Drug Profile
    • AF-219 - Drug Profile
    • AM-0010 - Drug Profile
    • AMAP-102 - Drug Profile
    • Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile
    • BG-00011 - Drug Profile
    • BMS-986020 - Drug Profile
    • BOT-191 - Drug Profile
    • CC-539 - Drug Profile
    • CC-90001 - Drug Profile
    • CGEN-25009 - Drug Profile
    • CKD-942 - Drug Profile
    • CM-101 - Drug Profile
    • CMYJH-01 - Drug Profile
    • CT-2009 - Drug Profile
    • D-9030 - Drug Profile
    • Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
    • FG-3019 - Drug Profile
    • GBT-1118 - Drug Profile
    • GBT-440 - Drug Profile
    • GKT-831 - Drug Profile
    • GLPG-1690 - Drug Profile
    • GSK-3008348 - Drug Profile
    • HEC-00000585 - Drug Profile
    • HL-156FIB - Drug Profile
    • HR-017 - Drug Profile
    • IBIOCFB-03 - Drug Profile
    • ICG-001 - Drug Profile
    • ISTH-0047 - Drug Profile
    • IVA-337 - Drug Profile
    • KAR-5585 - Drug Profile
    • KBP-7018 - Drug Profile
    • KD-025 - Drug Profile
    • KTN-0158 - Drug Profile
    • lebrikizumab - Drug Profile
    • LT-0011 - Drug Profile
    • LTI-03 - Drug Profile
    • MMI-0100 - Drug Profile
    • Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD - Drug Profile
    • MOR-107 - Drug Profile
    • NAS-911 - Drug Profile
    • Neumomir - Drug Profile
    • OLX-201 - Drug Profile
    • omipalisib - Drug Profile
    • P-013 - Drug Profile
    • PBF-1129 - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4425 - Drug Profile
    • pirfenidone - Drug Profile
    • PRM-151 - Drug Profile
    • PUR-1500 - Drug Profile
    • PXS-4820 - Drug Profile
    • RBM-005 - Drug Profile
    • RBM-006 - Drug Profile
    • Refacell-IPF - Drug Profile
    • RP-6503 - Drug Profile
    • RT-234 - Drug Profile
    • SAR-156597 - Drug Profile
    • SD-560 - Drug Profile
    • SM-04646 - Drug Profile
    • Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
    • Small Molecules for COPD and IPF - Drug Profile
    • Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
    • SPL-334 - Drug Profile
    • Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
    • Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
    • Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
    • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
    • TD-139 - Drug Profile
    • tipelukast - Drug Profile
    • vismodegib - Drug Profile
    • YH-siRNA1 - Drug Profile
    • ZL-2102 - Drug Profile
  • Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates
  • Idiopathic Pulmonary Fibrosis - Dormant Projects
  • Idiopathic Pulmonary Fibrosis - Discontinued Products
  • Idiopathic Pulmonary Fibrosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2016
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Antitope Limited, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Biogen, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2016
  • Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2016
  • Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2016
  • Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top